What drugs is used in combination with erlotinib to treat pancreatic cancer?

1.Gemcitabine: Combination therapy of erlotinib and gemcitabine is a common regimen in the treatment of pancreatic cancer. The combination has shown some efficacy in advanced or metastatic pancreatic cancer, particularly in those who are epidermal growth factor receptor (EGFR) positive.

Studies have shown that erlotinib combined with gemcitabine can extend the median progression-free survival of patients compared with gemcitabine alone, although this extension may be relatively limited.

2.Capecitabine: Erlotinib can also be used in combination with capecitabine for the treatment of pancreatic cancer. This combination regimen has shown efficacy and safety in some studies in patients with locally advanced or metastatic pancreatic cancer.

For example, in one study, patients in the observation group received a regimen of erlotinib combined with capecitabine, of which 2 patients achieved partial remission, 10 patients had stable disease, and the disease control rate reached 60%.

3.Oncolytic virus therapy: In addition to traditional chemotherapy drugs, erlotinib can also be used in combination with oncolytic virus therapy. Oncolytic viruses are an emerging treatment method that directly attack cancer cells by injecting specific viruses. In certain clinical trials, combination therapy with erlotinib and oncolytic viruses such as HF10 and gemcitabine has shown safety and efficacy in patients with unresectable locally advanced pancreatic cancer.

Combined use may increase the risk of side effects, such as diarrhea, rash, liver function abnormalities, etc. Therefore, it is necessary to closely monitor the patient's response during treatment and adjust the treatment plan in a timely manner. Each patient may respond differently to medications, so combination regimens should be individualized based on the patient's specific circumstances.